diphtheria, tetanus and pertussis combined vaccine (DTacP booster) / Sinopharm - LARVOL DELTA

Nonclinical safety and immunogenicity assessment of a combined DTacP vaccine in animal models. (PubMed, J Appl Toxicol) - "In the repeat-dose toxicity study, where five intramuscular doses were administered every 2 weeks, gross autopsy and histopathological examination revealed no vaccine-related systemic pathological changes in rats, with dose site irritant reactions mostly recovered at the end of recovery period. In conclusion, the vaccine demonstrated good local and systemic tolerance, supporting its clinical development."

Journal • Preclinical • Allergy • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus

A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (clinicaltrials.gov) - P3 | N=2898 | Active, not recruiting | Sponsor: China National Biotec Group Company Limited | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2023 ➔ Sep 2023

Enrollment closed • Trial primary completion date • Cough • Infectious Disease • Pertussis • Respiratory Diseases • Tetanus • ER

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models. (PubMed, Hum Vaccin Immunother) - "The DTacP-sIPV-Hib combination vaccine is safe and immunogenic in animal models. Three doses of the vaccine elicited satisfactory antibody responses in mice, rats, and cynomolgus monkeys."

Journal • Preclinical • Infectious Disease • Influenza • Pertussis • Respiratory Diseases • Tetanus